Skip to content

M100907, a selective 5-HT(2A) receptor antagonist, attenuates phencyclidine-induced Fos expression in discrete regions of rat brain.

T Habara, T Hamamura, M Miki, K Ohashi, S Kuroda

European journal of pharmacology April 13, 2001 DOI: 10.1016/s0014-2999(01)00926-8 via PubMed

Summary

AI-generated from the abstract

The selective 5-HT2A receptor antagonist M100907 attenuates phencyclidine (PCP)-induced Fos expression in specific rat brain regions. PCP (5 mg/kg) induced Fos expression in the cingulate cortex area 3, agranular insular cortex, piriform cortex, nucleus accumbens, anterior paraventricular thalamic nucleus, and ventral lateral septal nucleus. Pretreatment with M100907 (0.5 mg/kg) reduced Fos expression in the nucleus accumbens core and shell, agranular insular cortex, and piriform cortex, but not in other regions. M100907 alone did not induce Fos expression in any region, including the dorsolateral caudate/putamen. These results indicate that 5-HT2A receptor antagonism attenuates Fos expression in a regionally specific manner in the PCP model of psychosis.

Study at a glance

Characteristics Experimental study Peer reviewed
Population Rat brain
Interventions M100907 PCP
Dose PCP 5 mg/kg, M100907 0.5 mg/kg
Key finding M100907 attenuated PCP-induced Fos expression in the nucleus accumbens core, shell, agranular insular cortex, and piriform cortex, but not in other regions.

Abstract

5-HT and dopamine receptor antagonists have become widely used as atypical antipsychotics. Although 5-HT(2A) receptor antagonistic activity is thought to contribute to the atypical aspects of these agents, the precise mechanism remains unknown. M100907 (R(+)-alpha(2,3-dimethoxyphenyl)-1-[2(4-fluorophenyl)ethyl)]-4-piperidine -methanol), a selective 5-HT(2A) receptor antagonist, is reported to attenuate phencyclidine (PCP)-induced locomotion in rodents. For the purpose of identifying regions in which M100907 exerts its effect, we investigated the effects of M100907 on PCP-induced Fos expression in rat brain. PCP (5 mg/kg, subcutaneously, s.c.) induced Fos expression in the cingulate cortex area 3, the agranular insular cortex, the piriform cortex, the nucleus accumbens, the anterior paraventricular thalamic nucleus and the ventral lateral septal nucleus. Pretreatment with M100907 (0.5 mg/kg, s.c.) attenuated Fos expression induced by PCP in the nucleus accumbens core, the shell, the agranular insular cortex and the piriform cortex. M100907 did not induce Fos expression in any of the regions investigated including the dorsolateral caudate/putamen when given alone. These results indicate that 5-HT(2A) receptor antagonism attenuates Fos expression in a regionally specific manner in rat brain in the PCP model of psychosis.

Comments

No comments yet.

Log in to comment